GlycoNex (ROCO:4168) FCF Margin % : -1,990.06% (As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is GlycoNex FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. GlycoNex's Free Cash Flow for the three months ended in Dec. 2024 was NT$-63.24 Mil. GlycoNex's Revenue for the three months ended in Dec. 2024 was NT$3.18 Mil. Therefore, GlycoNex's FCF Margin % for the quarter that ended in Dec. 2024 was -1,990.06%.

As of today, GlycoNex's current FCF Yield % is -9.97%.

The historical rank and industry rank for GlycoNex's FCF Margin % or its related term are showing as below:

ROCO:4168' s FCF Margin % Range Over the Past 10 Years
Min: -102593.31 Med: -15351.87 Max: -585.8
Current: -1749.84

During the past 13 years, the highest FCF Margin % of GlycoNex was -585.80%. The lowest was -102593.31%. And the median was -15351.87%.

ROCO:4168's FCF Margin % is ranked worse than
82.2% of 1017 companies
in the Biotechnology industry
Industry Median: -142.95 vs ROCO:4168: -1749.84

GlycoNex FCF Margin % Historical Data

The historical data trend for GlycoNex's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex FCF Margin % Chart

GlycoNex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-32,697.12

-2,697.72

-585.80

-8,156.65

-1,749.84

GlycoNex Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-646.27	-101,447.37	-1,731.64	-1,990.06

Competitive Comparison of GlycoNex's FCF Margin %

For the Biotechnology subindustry, GlycoNex's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlycoNex's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's FCF Margin % distribution charts can be found below:

* The bar in red indicates where GlycoNex's FCF Margin % falls into.

Save Embed

;

Save Embed

;

GlycoNex FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

GlycoNex's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-257.244	/	14.701
	=	-1,749.84 %

GlycoNex's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-63.244	/	3.178
	=	-1,990.06 %

GlycoNex FCF Margin % Related Terms

Thank you for viewing the detailed overview of GlycoNex's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

GlycoNex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221

Website

http://www.glyconex.com.tw

GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The Company also provides antibody research services to its academic and industrial clients. The other services provided by the firm include functional evaluation and antibody engineering. The company has two segments which are antibody new drugs and exclusive investment. It earns the majority of its revenue from the antibody new drugs segment.

GlycoNex Headlines

No Headlines